1.14

2.70% +0.03

After Hours: 1.14

Protalix BioTherapeutics Inc. (PLX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Protalix BioTherapeutics Inc. stock is currently priced at $1.14, with a 24-hour trading volume of 225.16K. It has seen a +2.70% increased in the last 24 hours and a -2.56% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.11 pivot point. If it approaches the $1.16 resistance level, significant changes may occur.

Previous Close:

$1.11

Open:

$1.13

24h Volume:

225.16K

Market Cap:

$83.58M

Revenue:

$63.63M

Net Income/Loss:

$10.62M

P/E Ratio:

57.00

EPS:

0.02

Net Cash Flow:

$-8.64M

1W Performance:

+0.00%

1M Performance:

-2.56%

6M Performance:

-24.00%

1Y Performance:

-65.14%

1D Range:

$1.12

$1.16

52W Range:

$1.07

$3.31

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Name

Protalix BioTherapeutics Inc.

Sector

Healthcare (1216)

Industry

Biotechnology (698)

Phone

972 4 988 9488

Address

2 Snunit Street, Science Park PO Box 455, Karmiel

Employee

190

Twitter

@Protalix_Bio

Next Earnings Date

2024-05-10

Latest SEC Filings

PLX's Discussions on Twitter

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy
Apr-17-17	Reiterated	Rodman & Renshaw	Buy
Apr-04-16	Initiated	Rodman & Renshaw	Buy
Apr-23-15	Upgrade	Jefferies	Hold → Buy
Nov-12-14	Reiterated	R. F. Lafferty	Buy
Jan-24-14	Initiated	R. F. Lafferty	Buy
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold
May-02-12	Reiterated	Oppenheimer	Outperform
Apr-30-12	Downgrade	Auriga	Buy → Hold
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy
Nov-09-10	Reiterated	Oppenheimer	Outperform
Oct-14-10	Reiterated	UBS	Buy
Dec-02-09	Reiterated	Hapoalim	Outperform
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform
Dec-01-08	Reiterated	Oppenheimer	Outperform
Mar-11-08	Initiated	UBS	Buy
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform

View All

Protalix BioTherapeutics Inc. Stock (PLX) Latest News

Déclaration des transactions sur actions propres n 2024/07

GlobeNewswire Inc.

Pluxee affiche une performance solide au premier semestre et relève ses objectifs de croissance organique du chiffre d’affaires et de marge d’EBITDA récurrent pour l’exercice fiscal 2024

GlobeNewswire Inc.

Protalix BioTherapeutics Inc. Stock (PLX) Financials Data

Protalix BioTherapeutics Inc. (PLX) Revenue 2024

PLX reported a revenue (TTM) of $63.62 million for the quarter ending September 30, 2023, a +33.75% rise year-over-year.

Protalix BioTherapeutics Inc. (PLX) Net Income 2024

PLX net income (TTM) was $10.62 million for the quarter ending September 30, 2023, a +159.46% increase year-over-year.

Protalix BioTherapeutics Inc. (PLX) Cash Flow 2024

PLX recorded a free cash flow (TTM) of -$8.64 million for the quarter ending September 30, 2023, a +69.53% increase year-over-year.

Protalix BioTherapeutics Inc. (PLX) Earnings per Share 2024

PLX earnings per share (TTM) was $0.05 for the quarter ending September 30, 2023, a +113.51% growth year-over-year.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.